Holen Sie sich die Stockscreener-App
3.13
5.44%
-0.18
Handel nachbörslich:
3.26
0.13
+4.15%
Aclaris Therapeutics Inc Aktie (ACRS) Neueste Nachrichten
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update - Investing News Network
Aclaris Therapeutics Highlights AD and Asthma Data Catalysts at Oppenheimer Healthcare Conference - MarketBeat
Aclaris Therapeutics (ACRS) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance
Aclaris Therapeutics Inc earnings missed by $0.01, revenue fell short of estimates - Investing.com UK
Aclaris Therapeutics Q4 Earnings Summary & Key Takeaways - Benzinga
Aclaris Therapeutics Initiates Phase 1b Proof-of-Concept Trial in Patients with Asthma with its Novel Bispecific Anti-TSLP/IL-4Rα Antibody ATI-052 - The Manila Times
Aclaris tests experimental asthma antibody in new human trial - Stock Titan
Aclaris Therapeutics Inc expected to post a loss of 15 cents a shareEarnings Preview - TradingView
Market Rankings: Whats the beta of Seacoast Banking Corporation of Florida stockJuly 2025 Chart Watch & AI Powered Market Entry Ideas - baoquankhu1.vn
Will Aclaris Therapeutics Inc. stock recover faster than peersWeekly Market Report & Community Driven Trade Alerts - mfd.ru
Aclaris Therapeutics (ACRS) Projected to Post Earnings on Thursday - MarketBeat
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Aclaris Therapeutics Secures FDA Clearance for ATI-052 Clinical Trial - MSN
Aclaris Therapeutics Touts TSLP and ITK Pipeline, Sets Up Multiple Clinical Readouts for 2026 - MarketBeat
Aclaris at Guggenheim Summit: Strategic Biotech Developments By Investing.com - Investing.com Nigeria
Aclaris at Guggenheim Summit: Strategic Biotech Developments - Investing.com
What’s the beta of Aclaris Therapeutics Inc. stock2025 Fundamental Recap & Long-Term Investment Growth Plans - mfd.ru
Atopic Dermatitis Market to hit $31.68 billion by 2033 | Major - openPR.com
February 2026's Promising Penny Stocks To Consider - Yahoo Finance
Aclaris lines up February spotlight at major biotech investor conferences - MSN
Aclaris Lines Up February Spotlight at Major Biotech Investor Conferences - MyChesCo
Aclaris Therapeutics to Participate in Two February Healthcare Conferences - Investing News Network
Experimental hair-loss drug sparks rapid regrowth in severe alopecia study - MSN
There's Reason For Concern Over Aclaris Therapeutics, Inc.'s (NASDAQ:ACRS) Massive 25% Price Jump - simplywall.st
Experimental Hair-Loss Drug Sparks Rapid Regrowth in Severe Alopecia Study - MyChesCo
Aclaris joins Nasdaq biotech index, marking milestone for clinical-stage firm - MSN
Downgrade Watch: Whats the fair value of Aclaris Therapeutics Inc stock2025 Market Sentiment & AI Forecast for Swing Trade Picks - baoquankhu1.vn
Craig-Hallum initiates coverage on Aclaris Therapeutics stock with Buy rating - Investing.com Canada
Looking Into Aclaris Therapeutics Inc's Recent Short Interest - Benzinga
Aclaris Therapeutics (NASDAQ:ACRS) Receives “Buy” Rating from HC Wainwright - Defense World
Aclaris ATI-2138 Shows Superior Efficacy in Hair Loss Treatment - intellectia.ai
Aclaris Therapeutics' (ACRS) Buy Rating Reaffirmed at HC Wainwright - MarketBeat
Aclaris stock gets Buy rating reaffirmed by H.C. Wainwright after positive preclinical results - Investing.com Canada
Aclaris reports positive preclinical results for hair loss drug By Investing.com - Investing.com Canada
Aclaris Hair Loss Drug Shows Faster Results Than Pfizer's Drug - Benzinga
Aclaris reports positive preclinical results for hair loss drug - Investing.com
Aclaris Therapeutics' ATI-2138 Shows Superior Efficacy Against Ritlecitinib in Alopecia Universalis Model - Quiver Quantitative
Aclaris Therapeutics’ Novel ITK/JAK3 Inhibitor ATI-2138 - GlobeNewswire
Aclaris Therapeutics (NASDAQ:ACRS) versus Vivani Medical (NASDAQ:VANI) Head to Head Review - Defense World
Investor Alert: Common Warts Market Set for Rapid Growth – DelveInsight | Nielsen BioSciences, Verrica Pharmaceutical, Kino Pharma, Iwaki Pharma, Aclaris Therapeutics - Barchart.com
Aclaris Therapeutics, Inc.'s (NASDAQ:ACRS) high institutional ownership speaks for itself as stock continues to impress, up 72% over last week - simplywall.st
Market Rankings: What is Aclaris Therapeutics Incs book value per shareProfit Target & High Return Trade Opportunity Guides - baoquankhu1.vn
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World
Aclaris Therapeutics (NASDAQ:ACRS) nasdaq top 100 Clinical Pipeline - Kalkine Media
Aclaris pushes new antibody into skin disease trial, eyes asthma next - MSN
Aclaris Therapeutics Launches Phase 2 Trial for Promising Atopic Dermatitis Treatment - MSN
ACRS: Analyst Maintains Buy Rating and $16 Price Target | ACRS S - GuruFocus
Aclaris Therapeutics (NASDAQ:ACRS) Receives Buy Rating from HC Wainwright - MarketBeat
There's Reason For Concern Over Aclaris Therapeutics, Inc.'s (NASDAQ:ACRS) Massive 41% Price Jump - 富途牛牛
0.11%
0.59%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):